Abstract

HTA29 Analysis of the Change of the Added Benefit and Respective Reasons in Renewed Regular Benefit Assessments of Orphan Drugs Due to Exceeding the Sales Threshold in Germany

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Analyse von Orphan- Drug-Verfahren in der frühen Nutzenbewertung: RCTs versus best-verfügbare vergleichende Evidenz
Dr Rer Nat Gerrit Müller ... Dr Rer Nat Lena Fanter
Monitor Versorgungsforschung | VOL. 16
Dr Rer Nat Gerrit Müller, et. al.Dr Rer Nat Gerrit Müller ... Dr Rer Nat Lena Fanter
14 Mar 2023
HTA46 Outcomes of Benefit Assessments of Orphan Drugs Without Orphan Designation in Germany
L Frick ... M Schönermark
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 25
L Frick, et. al.L Frick ... M Schönermark
01 Dec 2022
Relationship Between The Price Differences In Orphan Drugs With More Than One Benefit Assessment In Amnog And The Potential Influencing Factors
M Hinnenthal ... D Bonduelle
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 20
M Hinnenthal, et. al.M Hinnenthal ... D Bonduelle
01 Oct 2017
A journey of hope: lessons learned from studies on rare diseases and orphan drugs
M Wästfelt ... B Fadeel
Acta Medica Scandinavica | VOL. 260
M Wästfelt, et. al.M Wästfelt ... B Fadeel
15 Jun 2006
View more papers

More From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Paper Title
Journal
Date
Author
The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set
-
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
--
21 Jun 2024
Market entry agreements for innovative pharmaceuticals subject to indication broadening: a case study for pembrolizumab in the Netherlands.
Renaud J S D Heine ... Carin A Uyl-De Groot
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
Renaud J S D Heine, et. al.Renaud J S D Heine ... Carin A Uyl-De Groot
21 Jun 2024
MSR99 A Stacked Ensemble Approach for Building Composite Measure Models in Healthcare
P Shi ... S Zhang
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 27
P Shi, et. al.P Shi ... S Zhang
15 Jun 2024
EE98 A Theory-Based Framework to Incorporate Health Equity in Economic Assessments
S Subramanian ... S Hoover
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 27
S Subramanian, et. al.S Subramanian ... S Hoover
15 Jun 2024
View more papers